{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:56:16Z","timestamp":1760241376662,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T00:00:00Z","timestamp":1520640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The incidence of antimicrobial resistance (AMR) worldwide is increasing as the pipeline for the development of new chemotherapeutic entities is decreasing. Clearly, overexposure to antibiotics, including excessive dosing, is a key factor that fuels AMR. In fact, most of the new antibacterial agents under development are derivatives of existing classes of antibiotics. Novel approaches involving unique antimicrobial combinations, targets, and\/or delivery systems are under intense investigation. An innovative combination of active pharmaceutical ingredients (APIs) consisting of antimicrobial drug(s), krill-oil-based phospholipids, and omega-3 fatty acid triglycerides, that may extend the therapeutic viability of currently effective antibiotics, at least until new chemical entities are introduced, is described.<\/jats:p>","DOI":"10.3390\/antibiotics7010022","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T13:13:48Z","timestamp":1520860428000},"page":"22","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potentially Important Therapeutic Interactions between Antibiotics, and a Specially Engineered Emulsion Drug Vehicle Containing Krill-Oil-Based Phospholipids and Omega-3 Fatty Acids"],"prefix":"10.3390","volume":"7","author":[{"given":"David","family":"Driscoll","sequence":"first","affiliation":[{"name":"Stable Solutions LLC, Goleta, CA 93117, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,3,10]]},"reference":[{"key":"ref_1","unstructured":"Allergan, AstraZeneca, Cipla, and DSM Sinochem Pharmaceuticals (2016). Industry Roadmap for Progress on Combating Antimicrobial Resistance, Wockhardt."},{"key":"ref_2","unstructured":"Talkington, K., Shore, C., and Kothari, P. (2016). A Scientific Roadmap for Antibiotic Discovery, The Pew Charitable Trust."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10928-017-9506-4","article-title":"What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles","volume":"44","author":"Bush","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: Resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","article-title":"A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens","volume":"46","author":"Bush","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Crommelin, D.J.A., and de Vlieger, J.S.B. (2015). Analytical methods for determining the size (distribution) in parenteral dispersions. Non-Biological Complex Drugs, Springer.","DOI":"10.1007\/978-3-319-16241-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.ejphar.2011.05.085","article-title":"Fatty acids and inflammation: The cutting edge between food and pharma","volume":"668","author":"Calder","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(1992). American College of Chest Physicians\/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med., 20, 864\u2013874.","DOI":"10.1097\/00003246-199206000-00025"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jama.1995.03520260039030","article-title":"The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study","volume":"273","author":"Pittet","year":"1995","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3945\/ajcn.112.046573","article-title":"Three short perioperative infusions of n-3 PUFAs reduce the systemic inflammation induced by cardiopulmonary bypass surgery: A randomized controlled trial","volume":"97","author":"Berger","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3945\/ajcn.2009.27951","article-title":"Rapid cellular enrichment of eicosapentaenoate after single intravenous injection of a novel medium-chain triacylglycerol:fish oil emulsion in humans","volume":"91","author":"Carpentier","year":"2010","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM198902023200501","article-title":"The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells","volume":"320","author":"Endres","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1097\/CCM.0b013e3181b0266c","article-title":"Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose defining trial","volume":"37","author":"Dellenger","year":"2009","journal-title":"Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000480424","article-title":"Endotoxin effects on cardiac and renal functions and cardiorenal syndromes","volume":"44","author":"Virzi","year":"2017","journal-title":"Blood Purif."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1745-6215-15-218","article-title":"The EUPHRATES trial (Evaluating the Use of Polymyxin B. Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxinemia and Septic shock): Study protocol for a randomized controlled trial","volume":"15","author":"Klem","year":"2014","journal-title":"Trials"},{"key":"ref_17","unstructured":"Iba, T., and Fowler, L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J. Intensive Care."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"PROWESS-SHOCK Study Group","volume":"366","author":"Ranieri","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bonaterra, G.A., Driscoll, D., Schwarzbach, H., and Kinscherf, R. (2017). Krill oil-in-water emulsion protects against lipopolysaccharide-induced proinflammatory activation of macrophages in vitro. Mar. Drugs, 15.","DOI":"10.3390\/md15030074"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0148607116673187","article-title":"Pharmaceutical and clinical aspects of lipid injectable emulsions","volume":"41","author":"Driscoll","year":"2017","journal-title":"JPEN"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1017\/S000711450784284X","article-title":"UK Food Strandards Agency Workshop Report: The effects of the dietary n6\/n3 fatty acid ratio on cardiovascular health","volume":"98","author":"Stanley","year":"2007","journal-title":"Br. J. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.CCM.0000206309.83570.45","article-title":"Omega-3 fatty acids improve the diagnosis-related outcome","volume":"34","author":"Heller","year":"2006","journal-title":"Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/01.CCM.0000257465.60287.AC","article-title":"Evaluation of clinical safety and beneficial effects of a fish oil-containing emulsion (Lipoplus, MLF541): Data from a prospective, randomized, multicenter trial","volume":"35","author":"Wichmann","year":"2007","journal-title":"Crit. Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(02)00036-4","article-title":"The influence of medium-chain triglycerides on the stability of all-in-one formulations","volume":"240","author":"Driscoll","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0022-2275(20)37575-1","article-title":"Incorporation of medium chain triacylglycerols into phospholipid bilayers: Effect of long chain triacyglycerols, cholesterol, and cholesterol esters","volume":"37","author":"Hamilton","year":"1996","journal-title":"J. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0378-5173(87)90195-5","article-title":"Aging effects in parenteral fat emulsions: The role of fatty acids","volume":"39","author":"Washington","year":"1987","journal-title":"Int. J. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s11095-006-9092-4","article-title":"Lipid injectable emulsions: Pharmacopeial and safety issues","volume":"23","author":"Driscoll","year":"2006","journal-title":"Pharm. Res."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/7\/1\/22\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:56:30Z","timestamp":1760194590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/7\/1\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["antibiotics7010022"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics7010022","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2018,3,10]]}}}